LRRK2 and Parkinson disease: To assess the potential of mfNPC-derived hMOs for PD modeling, organoids were generated from healthy control (H-lines)- and from patient-specific iPSCs carrying the PD-associated LRRK2-G2019S mutation (P-lines).